Mulabegović Nedzad, Rakanović-Todić Maida
Institut za farmakologiju, klinicku farmakologiju i toksikologiju, Medicinski fakultet Univerziteta u Sarajevu.
Med Arh. 2008;62(1):41-4.
ENKORTEN is newly registered drug in Bosnia and Herzegovina. It consists of two peptide components: met-enkephalin and alpha 1-13-corticotropine (alpha-ACTH 1-13), previously called alpha-melanocyte-stimulating hormone-like (alpha-MSH-like) Met-enkephalin and alpha-MSH exhibited cytoprotective effects individually and statistically significant additive effect was registered when both peptides were applied in combination on the model of ethanol induced gastric lesions in rats. Combination has immunomodulatory effects. Method of selective immunomodulation with antigens and peptides in immunological mediated diseases and malignant tumors is directed towards long-term remission without so many adverse effects characteristic for immunosuppressive drugs. Adverse reactions registered for so long with ENKORTEN were mild, reversible and usually developed during and immediately after drug application.
恩科尔滕是波斯尼亚和黑塞哥维那新注册的药物。它由两种肽成分组成:甲硫氨酸脑啡肽和α1-13促肾上腺皮质激素(α-促肾上腺皮质激素1-13),以前称为α-黑素细胞刺激素样(α-MSH样)。甲硫氨酸脑啡肽和α-MSH单独表现出细胞保护作用,当两种肽联合应用于大鼠乙醇诱导的胃损伤模型时,具有统计学意义的相加效应。该组合具有免疫调节作用。在免疫介导的疾病和恶性肿瘤中,用抗原和肽进行选择性免疫调节的方法旨在实现长期缓解,而没有免疫抑制药物特有的那么多不良反应。长期以来,恩科尔滕记录的不良反应轻微、可逆,通常在用药期间和用药后立即出现。